logo

Aeglea Biotherapeutics, Inc. (AGLE)



Trade AGLE now with
  Date
  Headline
5/5/2022 9:31:08 AM Aeglea BioTherapeutics Announces $45 Mln Registered Direct Offering Priced At Premium To Market
5/5/2022 6:40:26 AM Aeglea BioTherapeutics Q1 Loss/shr $0.37 Vs. Loss/shr $0.28 Prior Year
4/12/2022 6:04:18 AM Aeglea BioTherapeutics Submits BLA To FDA For Pegzilarginase For The Treatment Of Arginase 1 Deficiency
3/29/2022 8:01:39 AM Aeglea Reports Presentation Of Addl Data From Phase 3 Study Of Pegzilarginase For Treatment Of Arginase 1 Deficiency
2/10/2022 9:31:49 AM Aeglea BioTherapeutics Withdraws Public Offering
12/6/2021 6:33:19 AM Aeglea BioTherapeutics Phase 3 Study Of Pegzilarginase Meets Primary Endpoint In Patients With Arginase 1 Deficiency
11/4/2021 7:25:16 AM Aeglea BioTherapeutics Q3 Net Loss Widens To $20.3 Mln From $18.0 Mln Prior Year
8/5/2021 8:33:14 AM Aeglea BioTherapeutics Q2 Net Loss $6.8 Mln Vs. Net Loss $21.4 Mln Last Year
7/15/2021 8:39:59 AM Aeglea BioTherapeutics Appoints Jim Kastenmayer As General Counsel
7/8/2021 8:31:39 AM Aeglea BioTherapeutics Appoints Jonathan Alspaugh As CFO
6/24/2021 8:31:23 AM Aeglea BioTherapeutics Doses First Patient In Phase 1/2 Clinical Trial Of AGLE-177 For Homocystinuria
6/22/2021 8:32:21 AM Aeglea BioTherapeutics Appoints Marcio Souza To Board
5/3/2021 9:42:41 AM Aeglea Completes Patient Randomization For PEACE, Phase 3 Trial Of Pegzilarginase For Treatment Of Arginase 1 Deficiency